neurological Sci
FOXO4-DRI vs nearby senolytics Option FOXO4-DRI Type D-retro-inverso peptide Human trial stage None (preclinical only) Option Dasatinib + Quercetin (D+Q) Type Small-molecule drug + flavonoid Human trial stage Early human trials (e.g., Alzheimer's) Option Navitoclax Type BCL-2 family inhibitor Human trial stage Later-stage trials (e.g., myelofibrosis) D+Q and navitoclax are further along in humans but can affect healthy cells (e.g., low platelets)
Mechanical wounding induces a nitrosative stress by down-regulation of GSNO reductase and an increase in S -nitrosothiols in sunflower ( Helianthus annuus ) seedlings
Potential benefits: Extends beyond 30 days Convenient pre-measured doses Significant risks: Ice crystal formation can damage peptide structure Unknown potency loss during freezing/thawing No clinical data supporting this practice Recommendation: Not advised
Huseni MA, Wang L, Klementowicz JE, Yuen K, Breart B, Orr C, et al
You need peptide-specific guidance for the unique challenges women face after 40, not generic advice that doesn't address hormonal shifts
